Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBSNASDAQ:RGLSNASDAQ:RIGLNASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent BioSolutions$4.60-6.6%$8.14$1.82▼$15.10$250.22M1.82.63 million shs705,612 shsRGLSRegulus Therapeutics$1.58+5.0%$1.28$0.83▼$2.93$104.33M1.42637,457 shs1.30 million shsRIGLRigel Pharmaceuticals$17.87-2.8%$21.06$7.48▼$29.82$320.82M1.35206,405 shs110,955 shsVSTMVerastem$6.29-6.5%$6.13$2.10▼$13.52$325.66M0.6922,129 shs322,552 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent BioSolutions-4.78%-13.97%-31.54%-40.45%+89.79%RGLSRegulus Therapeutics+16.28%+10.29%+18.11%-2.60%-47.92%RIGLRigel Pharmaceuticals-3.11%-9.72%-14.47%+11.45%+23.42%VSTMVerastem+5.16%-1.32%+23.49%+81.40%-43.06%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEBSEmergent BioSolutions4.2171 of 5 stars3.51.00.04.62.52.51.3RGLSRegulus Therapeutics3.3626 of 5 stars3.54.00.00.03.93.30.0RIGLRigel Pharmaceuticals2.9646 of 5 stars3.21.00.00.03.32.51.9VSTMVerastem3.1189 of 5 stars4.51.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent BioSolutions 3.00Buy$14.33211.93% UpsideRGLSRegulus Therapeutics 3.00Buy$12.75709.52% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.80105.93% UpsideVSTMVerastem 3.00Buy$13.88120.55% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, RIGL, EBS, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/21/2025VSTMVerastemRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.003/17/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/14/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/6/2025RIGLRigel PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $55.003/5/2025RIGLRigel PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.003/5/2025RIGLRigel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.003/4/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent BioSolutions$1.01B0.25$0.52 per share8.92$12.51 per share0.37RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ARIGLRigel Pharmaceuticals$179.28M1.78N/AN/A($1.64) per share-10.90VSTMVerastem$10M32.39N/AN/A$2.27 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent BioSolutions-$760.50M-$3.73N/A2.22N/A-18.55%-9.91%-3.31%4/29/2025 (Estimated)RGLSRegulus Therapeutics-$30.04M-$0.87N/AN/AN/AN/A-53.07%-48.58%5/8/2025 (Estimated)RIGLRigel Pharmaceuticals-$25.09M$0.94128.2917.02N/A2.46%-14.80%3.03%5/6/2025 (Estimated)VSTMVerastem-$87.37M-$3.50N/AN/AN/AN/A-332.73%-73.97%5/8/2025 (Estimated)Latest RGLS, RIGL, EBS, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/A3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A3/4/2025Q4 2024RIGLRigel Pharmaceuticals$0.30$0.80+$0.50$0.80$57.59 million$57.60 million3/3/2025Q4 2024EBSEmergent BioSolutions-$0.35$0.05+$0.40-$0.58$254.67 million$194.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BioSolutionsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent BioSolutions1.302.881.47RGLSRegulus TherapeuticsN/A14.1514.14RIGLRigel PharmaceuticalsN/A1.961.87VSTMVerastem2.773.233.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent BioSolutions78.40%RGLSRegulus Therapeutics92.38%RIGLRigel Pharmaceuticals66.23%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipEBSEmergent BioSolutions1.20%RGLSRegulus Therapeutics4.35%RIGLRigel Pharmaceuticals9.04%VSTMVerastem2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent BioSolutions2,42054.34 million53.53 millionOptionableRGLSRegulus Therapeutics3066.24 million62.65 millionOptionableRIGLRigel Pharmaceuticals16017.86 million16.02 millionOptionableVSTMVerastem5051.49 million43.53 millionOptionableRGLS, RIGL, EBS, and VSTM HeadlinesRecent News About These CompaniesResearch Analysts Offer Predictions for Verastem Q1 EarningsMarch 28 at 6:00 AM | marketbeat.comWall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to TradeMarch 27 at 10:55 AM | zacks.comVerastem (NASDAQ:VSTM) Upgraded to Hold at StockNews.comMarch 26 at 3:35 AM | americanbankingnews.comVerastem (NASDAQ:VSTM) Upgraded to "Hold" at StockNews.comMarch 25 at 11:06 PM | marketbeat.comVerastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025March 25 at 4:35 PM | businesswire.comVerastem (NASDAQ:VSTM) Price Target Raised to $14.00March 25 at 9:42 AM | marketbeat.comVerastem (NASDAQ:VSTM) Given New $10.00 Price Target at HC WainwrightMarch 25 at 8:12 AM | marketbeat.comGuggenheim Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) StockMarch 25 at 2:52 AM | americanbankingnews.comVerastem price target raised to $14 from $13 at GuggenheimMarch 24, 2025 | markets.businessinsider.comVerastem CFO Daniel Calkins sells shares worth $630March 24, 2025 | investing.comVerastem price target raised to $10 from $7 at H.C. WainwrightMarch 24, 2025 | markets.businessinsider.comVerastem’s Promising Financial Outlook and Strategic Advancements Drive Buy RatingMarch 24, 2025 | tipranks.comRoyal Bank of Canada Cuts Verastem (NASDAQ:VSTM) Price Target to $14.00March 24, 2025 | americanbankingnews.comRosalind Advisors Inc. Takes Position in Verastem, Inc. (NASDAQ:VSTM)March 23, 2025 | marketbeat.comAlliance Global Partners Remains a Buy on Verastem (VSTM)March 22, 2025 | markets.businessinsider.comRoyal Bank of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock PriceMarch 22, 2025 | marketbeat.comBTIG Sticks to Its Buy Rating for Verastem (VSTM)March 21, 2025 | markets.businessinsider.comVerastem price target lowered to $14 from $16 at RBC CapitalMarch 21, 2025 | markets.businessinsider.comVerastem (NASDAQ:VSTM) Issues Quarterly Earnings ResultsMarch 21, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Announces Quarterly Earnings ResultsMarch 21, 2025 | marketbeat.comVerastem reports Q4 EPS (60c), consensus (74c)March 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGLS, RIGL, EBS, and VSTM Company DescriptionsEmergent BioSolutions NYSE:EBS$4.60 -0.33 (-6.61%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Regulus Therapeutics NASDAQ:RGLS$1.58 +0.08 (+5.00%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Rigel Pharmaceuticals NASDAQ:RIGL$17.87 -0.52 (-2.83%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$6.29 -0.44 (-6.52%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
